Mage-a3 peptides presented by hla class ii molecules

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/12 (2006.01) A61K 35/14 (2006.01) A61K 38/17 (2006.01) C07K 7/08 (2006.01) C07K 14/47 (2006.01) C07K 14/705 (2006.01) C07K 14/82 (2006.01) C07K 16/18 (2006.01) C07K 16/30 (2006.01) C12N 5/08 (2006.01) C12Q 1/02 (2006.01) G01N 33/566 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2443342

The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE- A3 gene.

La présente invention concerne des peptides de liaison HLA de classe II codés par le gène MAGE-A3 associé à la tumeur, ainsi que des acides nucléiques codant pour ces peptides et des anticorps liés à ces acides. Ces peptides stimulent l'activité et la prolifération des lymphocytes CD4?+¿ T. Cette invention concerne aussi des techniques et des produits permettant de diagnostiquer et de traiter des pathologies caractérisées par l'expression du gène MAGE-A3.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Mage-a3 peptides presented by hla class ii molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mage-a3 peptides presented by hla class ii molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mage-a3 peptides presented by hla class ii molecules will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1468503

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.